145 related articles for article (PubMed ID: 38366057)
1. Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy.
Chen Y; Chen C; Peng H; Lin S; Pan J; Zheng H; Zong J; Lin C
Sci Rep; 2024 Feb; 14(1):3950. PubMed ID: 38366057
[TBL] [Abstract][Full Text] [Related]
2. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
[TBL] [Abstract][Full Text] [Related]
3. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.
Yang JH; Sun XS; Xiao BB; Liu LT; Guo SS; Liang JD; Jia GD; Tang LQ; Chen QY; Mai HQ
BMC Cancer; 2021 May; 21(1):534. PubMed ID: 33975558
[TBL] [Abstract][Full Text] [Related]
4. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
5. Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.
Liu GY; Li Z; Chen XX; Xia WX; Yao HR; Xiang YQ
Head Neck; 2023 Oct; 45(10):2571-2579. PubMed ID: 37554098
[TBL] [Abstract][Full Text] [Related]
6. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
[TBL] [Abstract][Full Text] [Related]
7. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.
Li WZ; Hua X; Xie DH; Liang H; Liu GY; Xia WX; Xiang YQ
ESMO Open; 2021 Feb; 6(1):100004. PubMed ID: 33399071
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
Lin C; Lin S; Zhu L; Lin S; Pan J; Xu Y
BMC Cancer; 2022 Jan; 22(1):35. PubMed ID: 34983459
[TBL] [Abstract][Full Text] [Related]
9. Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study.
Zeng F; Lu T; Xie F; Chen L; Zhang L; Su Y; Yu Z; Xiao Y; Ao F; Li G; Chen Z; Gong X; Li J
Transl Oncol; 2021 Nov; 14(11):101187. PubMed ID: 34365221
[TBL] [Abstract][Full Text] [Related]
10. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
[TBL] [Abstract][Full Text] [Related]
11. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
[TBL] [Abstract][Full Text] [Related]
12. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma.
Xu H; Lu L; Lu T; Xu Y; Zong J; Huang C; Lin F; Zheng Y; Lin C; Lin S; Qiu S; Pan J; Lin S; Guo Q
Head Neck; 2021 Sep; 43(9):2602-2610. PubMed ID: 33904617
[TBL] [Abstract][Full Text] [Related]
13. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
14. The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
Wan Y; Tian L; Zhang G; Xin H; Li H; Dong A; Liang Y; Jing B; Zhou J; Cui C; Chen M; Sun Y; Xie C; Liu L; Shao Y
Radiother Oncol; 2019 Feb; 131():35-44. PubMed ID: 30773185
[TBL] [Abstract][Full Text] [Related]
15. Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases.
Lin C; Sun XS; Liu SL; Li XY; Lu N; Li XL; Tang LQ; Guo L
Cancer Res Treat; 2020 Jul; 52(3):855-866. PubMed ID: 32164051
[TBL] [Abstract][Full Text] [Related]
16. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
[TBL] [Abstract][Full Text] [Related]
17. A nomogram for predicting survival of nasopharyngeal carcinoma patients with metachronous metastasis.
Zeng Z; Shen L; Wang Y; Shi F; Chen C; Wu M; Bai Y; Pan C; Xia Y; Wu P; Li W
Medicine (Baltimore); 2016 Jul; 95(27):e4026. PubMed ID: 27399084
[TBL] [Abstract][Full Text] [Related]
18. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.
Lai C; Zhang C; Lv H; Huang H; Ke X; Zhou C; Chen H; Chen S; Zhou L
Cancer Med; 2021 Jun; 10(11):3511-3523. PubMed ID: 33973727
[TBL] [Abstract][Full Text] [Related]
20. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
Du C; Ni M; Jiang J; Kong F; Zhai R; Lv Y; Hu C; Ying H
Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3947-3956. PubMed ID: 34981158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
